Market closed
Immunovant/$IMVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunovant
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Ticker
$IMVT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
207
Website
Immunovant Metrics
BasicAdvanced
$2.6B
-
-$2.62
0.65
-
Price and volume
Market cap
$2.6B
Beta
0.65
52-week high
$32.95
52-week low
$15.00
Average daily volume
1.7M
Financial strength
Current ratio
6.039
Quick ratio
5.517
Total debt to equity
0.007
Management effectiveness
Return on assets (TTM)
-44.73%
Return on equity (TTM)
-74.17%
Valuation
Price to book
6.35
Price to tangible book (TTM)
6.35
Price to free cash flow (TTM)
-6.831
Growth
Earnings per share change (TTM)
44.23%
3-year earnings per share growth (CAGR)
25.88%
What the Analysts think about Immunovant
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Immunovant stock.
Immunovant Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Immunovant Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Immunovant News
AllArticlesVideos
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Seeking Alpha·2 weeks ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Investors Business Daily·2 weeks ago
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Reuters·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Immunovant stock?
Immunovant (IMVT) has a market cap of $2.6B as of April 03, 2025.
What is the P/E ratio for Immunovant stock?
The price to earnings (P/E) ratio for Immunovant (IMVT) stock is 0 as of April 03, 2025.
Does Immunovant stock pay dividends?
No, Immunovant (IMVT) stock does not pay dividends to its shareholders as of April 03, 2025.
When is the next Immunovant dividend payment date?
Immunovant (IMVT) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunovant?
Immunovant (IMVT) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.